相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Chen Chen Jiang et al.
CLINICAL CANCER RESEARCH (2011)
Treatment implications of the emerging molecular classification system for melanoma
Emanuela Romano et al.
LANCET ONCOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Advances in systemic treatment of melanoma
A. M. M. Eggermont
ANNALS OF ONCOLOGY (2010)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
Yongping Shao et al.
CANCER RESEARCH (2010)
Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIPL from degradation by the E3 ligase itch in human melanoma cells
F. Yang et al.
CELL DEATH AND DIFFERENTIATION (2010)
PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells
Edita Aksamitiene et al.
CELLULAR SIGNALLING (2010)
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
R. Kefford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
C. C. Jiang et al.
CELL DEATH & DISEASE (2010)
Small molecules and targeted therapies in distant metastatic disease
P. Hersey et al.
ANNALS OF ONCOLOGY (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Claudia Wellbrock et al.
PLOS ONE (2008)
Improving melanoma classification by integrating genetic and morphologic features
Amaya Viros et al.
PLOS MEDICINE (2008)
Management of metastatic melanoma
Hussein A. Tawbi et al.
SEMINARS IN ONCOLOGY (2007)
Confirmation of a BRAF mutation-associated gene expression signature in melanoma
Peter Johansson et al.
PIGMENT CELL RESEARCH (2007)
BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins
Arnim Weber et al.
JOURNAL OF CELL BIOLOGY (2007)
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Liqing Zhuang et al.
MODERN PATHOLOGY (2007)
Regulation of apoptosis by alternative pre-mRNA splicing
C Schwerk et al.
MOLECULAR CELL (2005)
Absence of V599E BRAF mutations in desmoplastic melanomas
JM Davison et al.
CANCER (2005)
Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway
S Sato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Signal-dependent regulation of splicing via phosphorylation of Sam68
N Matter et al.
NATURE (2002)
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability
GG McGill et al.
CELL (2002)
分享论文
